BIOTRONIK announces U.S. FDA approval of its Acticor Sky and Rivacor Sky ICD and CRT-D systems. The approvals expand the company’s cardiac rhythm portfolio with technologies designed to support physiology-driven therapies and streamline clinical workflows; the devices are slated for showcase at HRS 2026.

Apr 2026BIOTRONIK (official newsroom)News article

BIOTRONIK announces FDA approval for its Solia CSP S pacing lead. The company describes it as the first pacing lead to combine a stylet-driven platform with a fixed helix, designed specifically for Left Bundle Branch Area Pacing (LBBAP). The lead becomes commercially available in the United States with the approval.

Feb 2026BIOTRONIK (official newsroom)News article

BIOTRONIK reports the first human implantations of its LivIQ leadless pacemaker system in the BIO|CONCEPT.LivIQ pre-market clinical investigation. The implantations take place in Australia, and the company describes LivIQ as the world’s first leadless pacemaker to deliver AV-synchronous pacing using atrial electrical far-field signals.

Jan 2026BIOTRONIK (official newsroom)News article

Teleflex completes its acquisition of substantially all of BIOTRONIK's Vascular Intervention business under a definitive agreement signed February 27, 2025. The deal transfers BIOTRONIK's coronary and peripheral interventional portfolio to Teleflex.

Jul 2025Endovascular TodayNews article